Part:BBa_K1781001
HER2 (Human Epidermal Growth Factor 2) cytoplasmic domain
HER2 is the Human Epidermal Growth Factor 2 transmembrane receptor protein. It is located on all cells and when overexpressed this oncogene is known to induce some types of cancer. In recent years, it has been used as a biomarker. In this project, protein-protein interactions were analyzed and HER2 was identified as a perfect control. Its cytoplasmic tyrosine kinase domain was known to bind to antibodies such as trastuzumab, but more recently the affibody ZHER2 was created to bind to the protein with a higher affinity. In this case, we only needed the cytoplasmic domain for our use in the analysis of the HER2-ZHER2 binding.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21INCOMPATIBLE WITH RFC[21]Illegal BglII site found at 176
- 23COMPATIBLE WITH RFC[23]
- 25INCOMPATIBLE WITH RFC[25]Illegal NgoMIV site found at 19
Illegal AgeI site found at 592 - 1000INCOMPATIBLE WITH RFC[1000]Illegal BsaI.rc site found at 271
Illegal BsaI.rc site found at 589
Illegal SapI site found at 522
Functional Parameters
The Ramachandran plot shows the phi-psi torsion angles for all residues in the structure (except those at the chain termini). Glycine residues are separately identified by triangles as these are not restricted to the regions of the plot appropriate to the other sidechain types.
The colouring/shading on the plot represents regions with different favorability: the darkest areas (here shown in red) correspond to the "core" regions representing the most favourable combinations of phi-psi values.
Ideally, one would hope to have over 90 % of the residues in these "core" regions. The percentage of residues in the "core" regions is one of the better guides to stereochemical quality.
| None |